NEWRON PHARMACEUTICALS S.P.A. Shareholders accepted all motions at the AGM 2018
Milan, Italy - March 27, 2018 - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that shareholders either unanimously or with vast majorities approved all motions on the agenda of its shareholders' annual meeting held in Bresso (MI), Italy, today. About 24.9% of Newron's total capital of 17,844,345 shares were represented at the meeting.
Press Release (PDF)
| Provider | Channel | Contact | ||
|---|---|---|---|---|
|
EQS Group Ltd., Switzerland switzerland.eqs.com |
newsbox.ch www.newsbox.ch |
Provider/Channel related enquiries cs.switzerland@eqs.com +41 41 763 00 50 |
